Simmitinib clinical trials
How each study uses Simmitinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Simmitinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
3 studies that test it; most in 2024 (2)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2024 | 2 |
Who runs them
Industry 3 · Other 0
Shanghai Runshi Pharmaceutical Technology Co., Ltd (2) · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (1)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1, 1 in phase 3
Studies that test Simmitinib, phase 3 first.
- Jan 2027A Study of Simmitinib Versus Chemotherapy for Participants With Advanced Oesophageal Squamous Cell CarcinomaPhase 3 · Shanghai Runshi Pharmaceutical Technology Co., Ltd
Studies
Open first, then newest update. How each study uses Simmitinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- A Study of Simmitinib Versus Chemotherapy for Participants With Advanced Oesophageal Squamous Cell CarcinomaNot yet recruitingPhase 3Shanghai Runshi Pharmaceutical Technology Co., LtdNCT06656091Written as simmitinib
- A Study of Simmitinib Plus Irinotecan in Advanced Esophageal Squamous Cell CarcinomaRecruitingPhase 2Shanghai Runshi Pharmaceutical Technology Co., LtdNCT06512428Written as simmitinib plus irinotecan liposome
- A Phase I Trial of Simmitinib in Advanced Solid TumorsStatus unknownPhase 1CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT04058587Written as Simmitinib
Given beside what is tested · 2 — Simmitinib is usual care or a partner of the new treatment
- A PhaseⅠ/Ⅱ Study of Simmitinib or Irinotecan Liposomes Combined With DP303c in Gastric Adenocarcinoma or Gastroesophageal Junction AdenocarcinomaNot yet recruitingPhase 1/2Shanghai Runshi Pharmaceutical Technology Co., LtdNCT06577376Written as Simmitinib tablets
- A Study of Simmitinib Plus SG001 in Advanced Solid TumorsNot yet recruitingPhase 1/2Shanghai Runshi Pharmaceutical Technology Co., LtdNCT06132217Written as Simmitinib